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Abstract
Background: People with a DNA mismatch repair (MMR) gene mutation have a substan-
tially elevated risk of colorectal cancer (CRC) but the modifiers of this risk are not well es-
tablished. We investigated the association between dietary supplement intake and CRC
risk for carriers.
Methods: This study included 1966 (56% female) carriers of an MMR gene mutation (719
MLH1, 931 MSH2, 211 MSH6 and 105 PMS2) who were recruited from the USA, Canada,
Australia and New Zealand into the Colon Cancer Family Registry between 1997 and
2012. Information on lifestyle factors including supplement intake was collected at the
time of recruitment. Using Cox proportional hazards regression weighted to correct for
ascertainment bias, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs)
for associations between self-reported multivitamin, calcium and folic acid supplement
intake and CRC risk.
Results: Of 744 carriers with CRC, 18%, 6% and 5% reported intake of multivitamin, cal-
cium and folic acid supplements for at least 1 month, respectively, compared with 27%,
11% and 10% of 1222 carriers without CRC. After adjusting for identified confounding
variables, a decreased CRC risk was associated with multivitam inintake for at least 3
years (HR 0.47, 95% CI 0.32–0.69) and calcium intake for at least 3 years(HR 0.42, 95% CI
0.23–0.74), compared with never users. There was no evidence of an association be-
tween folic acid supplement intake and CRC risk (P ¼ 0.82).
Conclusion: Intake of multivitamin and calcium supplements might be associated with a
decreased risk of CRC for MMR gene mutation carriers.
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Introduction
Colorectal cancer (CRC) is the third most common cancer
in both men and women and the third leading cause of
cancer-related deaths in the USA.1 The lifetime risk of
CRC is 5% in men and 4.7% in women.1 Approximately
2–4% of all colorectal cancers,2–9 but 10–15% of colorec-
tal cancers diagnosed before age 50 years,2,3,10 are attribut-
able to Lynch syndrome. Lynch syndrome is an autosomal
dominant disorder of cancer predisposition caused by a
germline mutation in one of the DNA mismatch repair
(MMR) genes MLH1, MSH2, MSH6 and PMS2.11
Approximately 1 in 3100 people in the general population
carry a mutation in an MMR gene.12 MMR gene mutation
carriers have a substantially increased risk of colorectal
cancer (CRC) to age 70 years, estimated to be between
20% and 70% depending on sex and the mutated MMR
gene.13–16
Personal and lifestyle factors may modify the risk of
CRC for MMR gene mutation carriers. Identifying modi-
fiers of disease risk is important for understanding carcino-
genesis, as it may indicate potential initiators or promoters
of the disease. In addition, identifying potentially protect-
ive factors, or conversely, harmful and avoidable risk fac-
tors might provide opportunities for mutation carriers to
reduce their risk of cancer. Previous studies have reported
that increased body mass index (BMI),17–19 alcohol con-
sumption20 and cigarette smoking18,20–23 are associated
with an increased risk of CRC for mutation carriers,
whereas aspirin intake,24,25 and fruit and dietary fibre in-
take18 are associated with a decreased risk.
Key Messages
• People with a DNA mismatch repair gene mutation have a substantially elevated risk of colorectal cancer and several
other cancers.
• Almost nothing is known about lifestyle factors influencing the risk of colorectal cancer in these mutation carriers.
• Regular intake of multivitamin and calcium supplements for at least 3 years was found to be associated with an
approximately 50% reduced risk of colorectal cancer for people with mismatch repair gene mutations.
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For the general population, intake of multivitamin,26 cal-
cium27 and dietary folate or folic acid supplements28 have
been reported to be associated with a decreased risk of
CRC, although individual study findings have been incon-
sistent. In the current study, we report associations between
intake of multivitamin, calcium and folic acid supplements
and CRC risk for people with Lynch syndrome.
Materials and Methods
Study sample
The study sample comprised carriers of a germline patho-
genic mutation in an MMR gene, who had been recruited
by the Colon Cancer Family Registry. Detailed description
of the study design and recruitment strategies have been
previously published.29 Between 1997 and 2012, families
were recruited either via population-based probands who
were recently diagnosed with CRC and identified from
state or regional population cancer registries in the USA
(Washington, California, Arizona, Minnesota, Colorado,
New Hampshire, North Carolina and Hawaii), Australia
(Victoria) and Canada (Ontario), or via probands who
were members of, multiple-case cancer families referred to
family cancer clinics in the USA (Mayo Clinic, Rochester,
Minnesota and Cleveland Clinic, Cleveland, Ohio),
Canada (Ontario), Australia (Melbourne, Adelaide, Perth,
Brisbane, Sydney) and New Zealand (Auckland). Probands
were asked for permission to contact their relatives to seek
their enrolment in the Colon Cancer Family Registry.
Informed consent was obtained from all study participants
and the study protocol was approved by the institutional
research ethics review board at each recruitment centre.
Data Collection
Information on demographics, personal characteristics,
personal and family history of cancer, CRC screening,
colorectal polyps and polypectomy and other surgical pro-
cedures, as well as lifestyle factors including intake of
multivitamin, calcium and folic acid supplements, were ob-
tained from all probands and participating relatives, at the
time of recruitment. The information was collected using
standardized questionnaires via personal interviews, tele-
phone interviews or mails. The questionnaires are available
at: [http://coloncfr.org/questionnaires]. We attempted to
request and obtain blood samples from all participants and
tumour tissues from all CRC-affected participants.
MMR gene mutation testing
Testing for germline mutations in MLH1, MSH2, MSH6
and PMS2 was performed for all population-based
probands who had a colorectal tumour displaying evidence
of MMR-deficiency as evidenced by either tumour micro-
satellite instability (MSI) and/or loss of MMR-protein
expression by immunohistochemistry, and for the young-
est-onset CRC case from each clinic-based family regard-
less of tumour MMR-deficiency status. Details of germline
testing methods have been described elsewhere.30 Relatives
of the probands with a pathogenic MMR germline muta-
tion, who provided a blood sample, underwent testing for
the specific mutation identified in the proband. All pro-
bands and relatives with a pathogenic MMR gene muta-
tion were eligible for the current study.
Exposure definitions
Intakes of multivitamin, calcium and folic acid supple-
ments were the three main exposure variables. Ever users
of supplements were defined as those who answered ‘yes’
to ‘Have you ever taken [supplement] at least twice a week
for 1 month or longer?’ Never users were defined as those
who answered ‘no’ to ‘Have you ever taken [supplement]
at least twice a week for 1 month or longer?’ Duration of
supplement intake was defined as self-reported total num-
ber of years of supplement intake before age at CRC diag-
nosis or censored age. Given that the age at first intake of
these supplements was not reported, we estimated the age
at first intake by subtracting the reported duration of in-
take from the age at the baseline questionnaire, assuming
that the duration was continuous and recent. Frequency of
supplement intake was defined as self-reported weekly fre-
quency of supplement intake.
Statistical analysis
Proportional Cox regression, with age as the time scale,
was used to estimate hazard ratios (HRs) for associations
between multivitamin, calcium and folic acid supplement
intake and CRC risk for MMR gene mutation carriers.
Time at risk started at birth and ended at: age at diagnosis
of CRC (n ¼ 744); or age at diagnosis of non-colorectal
cancer (n ¼ 343); or first polypectomy (n ¼ 317); or inter-
view (n ¼ 562), whichever occurred first. We censored at
the age of first polypectomy to avoid potential bias, be-
cause polypectomy reduces CRC risk. We censored at age
of diagnosis of a non-colorectal cancer because intake of
supplements and CRC risk may be changed by diagnosis
and treatment of a non-colorectal cancer.31,32
As some carriers from this study were ascertained be-
cause they had CRC, and diagnosed at a young age, the
subject selection for testing for genetic mutations was not
random with respect to the CRC status. To reduce bias of
estimates of hazards, we adjusted for this non-random
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ascertainment by applying probability weights based on
the approach described by Antoniou et al.33 Weights were
calculated for the carriers with CRC and without CRC for
each age-stratum, so the proportion of carriers with CRC
at each age-stratum equalled that expected based on the
age-specific incidences of CRC for carriers.34
The proportional hazards (PH) assumption was tested
using the Schoenfeld and scaled Schoenfeld residuals.35
Univariable and multivariable models were fitted separ-
ately for intake of each supplement (multivitamin, calcium
and folic acid) as well as intake of two or more of the sup-
plements. The variables that we considered as potential
confounders are listed in Table 1. The variables that did
not meet the PH assumption were included in the model as
time-dependent covariates. Interactions were assessed by a
change in the log-likelihood ratio after the addition of a
cross-product term between the exposure and potential ef-
fect modifiers identified a priori (country of recruitment,
ascertainment method, mutated gene, sex and site of colo-
rectal cancer). The overall model fit was assessed using
Cox–Snell residuals as the time variable and plotting them
against the Nelson–Aalen cumulative hazard function.36
For multivariable models, missing data were handled
using both complete case analysis and multiple imput-
ations. Numbers of missing values for all the variables are
shown in Table 1. Missing data were imputed using
chained interactions, assuming that missingness was at ran-
dom.37 Outcome status, age at the time of colorectal can-
cer diagnosis or censored age, year of birth, country,
mutated gene, ascertainment method and whether the car-
rier was a proband were included in the imputation model;
50 imputed datasets were generated.
The following additional analyses were conducted:
(i) analysis restricted to carriers who were diagnosed with
CRC or censored within 5 years before interview, to reduce
survival bias; and (ii) analysis in which outcome was
defined as colorectal neoplasia, i.e. either CRC or colorec-
tal polyps.
The 95% confidence intervals (CIs) of HRs were calcu-
lated accounting for clustering by family membership to
allow for correlation of risk between relatives from the
same family, using the Huber–White robust variance cor-
rection.38,39 All statistical tests were two-sided. All ana-
lyses were performed using Stata 13.0.40
Results
From the Colon Cancer Family Registry, we identified a
total of 2003 carriers of a pathogenic mutation in an
MMR gene. Of these carriers, we excluded 11 (0.5%) who
were censored before 18 years of age and 26 (1.3%) with
missing data for all main exposure variables. A total of
1966 (56% female) carriers contributed to the analysis;
719 carried a germline mutation in MLH1, 931 in MSH2,
211 in MSH6 and 105 in PMS2. Carriers excluded due to
missing data did not differ in main characteristics from
those who were not excluded. Characteristics of the car-
riers included in the study are summarized in Table 1. For
carriers who were diagnosed with CRC or censored at an
age younger than age at interview, the mean time interval
between diagnosis or censored age and age at interview
was 9.6 [standard deviation (SD) 9.8] years for carriers
with CRC and 10.0 (SD 9.2) years for carriers without
CRC (P ¼ 0.40).
A total of 744 (38%) MMR mutation carriers were re-
ported to be diagnosed with CRC at a mean age of 42.4
(SD 10.5) years. Of these, 681 (91%) were confirmed by
pathology reports or medical records or cancer registry
linkage data. Overall, 18%, 6% and 5% of carriers af-
fected with CRC reported intake of multivitamin, calcium
and folic acid supplements, respectively, at least twice a
week for at least 1 month, compared with 27%, 11% and
10% of unaffected carriers. Intakes of multivitamin and
calcium supplements were higher in women than men and
in carriers from the USA than those from Canada,
Australia or New Zealand, and increased with age
(Table 2).
Overall, we found that intake of multivitamin and cal-
cium supplements was associated with a decreased risk of
CRC compared with never users (HR 0.55, 95% CI 0.40–
0.75; and HR 0.46, 95% CI 0.30–0.71, respectively).
There was a decreased risk of CRC associated with an
increased duration of multivitamin intake ( 3 years: HR
0.47, 95% CI 0.32–0.69; per year: HR 0.95, 95% CI
0.91–0.98), and calcium intake ( 3 years: HR 0.42, 95%
CI 0.23–0.74; per year: HR 0.90, 95% CI 0.83–0.98).
There was no evidence of an association between folic acid
supplement intake and CRC risk (P ¼ 0.82). The results
from the multiple imputation analysis were similar to the
complete case analysis (Table 3). When we additionally ad-
justed for recent BMI, red meat intake and fruit and vege-
table intake in the multiple imputation analysis, the results
were similar to the main analysis (Supplementary Table 1,
available as Supplementary data at IJE online). There was
no evidence of interactions between each supplement in-
take and country of recruitment, ascertainment method,
mutated gene, sex or site of colorectal cancer
(Supplementary Table 2, available as Supplementary data
at IJE online).
There was an inverse association between multivitamin
supplement intake and CRC risk for both males and fe-
males (HR 0.45, 95% CI 0.28–0.72, and HR 0.64, 95%
CI 0.43–0.95, respectively). There was an inverse associ-
ation with calcium supplement intake in women (HR 0.63,
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Table 1. Characteristics of carriers of germline mutations in DNA mismatch repair genes
Exposure variable No colorectal cancer
(n 5 1222 (62.2%))
Colorectal cancer
(n 5 744 (37.8%))
Total
(n 5 1966)
Sex, n (%)
Female 767 (62.8) 341 (45.8) 1,108 (56.4)
Male 455 (37.2) 403 (54.2) 858 (43.6)
Country of recruitment, n (%)
Australia or New Zealand 707 (57.9) 349 (46.9) 1,056 (53.7)
USA 349 (28.6) 278 (37.4) 627 (31.9)
Canada 166 (13.6) 117 (15.7) 283 (14.4)
Race, n (%)
Caucasian 1160 (94.9) 675 (90.7) 1,835 (93.3)
Other 43 (3.5) 58 (7.8) 101 (5.1)
Missing 19 (1.6) 11 (1.5) 30 (1.5)
Age (years)a
mean (SD) 41.5 (13.1) 42.4 (10.5) 41.8 (12.2)
median [range] 41 [18 - 85] 42 [19 - 75] 42 [18 - 85]
Year of birth, n (%)
1914–43 250 (20.5) 210 (28.2) 460 (23.4)
1944–54 265 (21.7) 214 (28.8) 479 (24.4)
1955–65 304 (24.9) 212 (28.5) 516 (26.3)
1966–90 403 (33.0) 108 (14.5) 511 (26.0)
Ascertainment
Population 970 (79.4) 491 (66.0) 1461 (74.3)
Cancer clinic 252 (20.6) 253 (34.0) 505 (25.7)
Education level, n (%)
Primary or less 11 (0.9) 17 (2.3) 28 (1.4)
Some high school 229 (18.7) 158 (21.2) 387 (19.7)
Completed high school / some tertiary 426 (34.9) 245 (32.9) 671 (34.1)
Vocational/technical school 222 (18.2) 121 (16.3) 343 (17.5)
University degree 324 (26.5) 192 (25.8) 516 (26.3)
Missing 10 (0.8) 11 (1.9) 21 (1.1)
MMR gene mutated, n (%)
MLH1 401 (32.8) 318 (42.7) 719 (36.6)
MSH2 613 (50.2) 318 (42.7) 931 (47.4)
MSH6 149 (12.2) 62 (8.3) 211 (10.7)
PMS2 59 (4.8) 46 (6.2) 105 (5.3)
Number of screening colonoscopies
0 402 (32.9) 184 (24.7) 586 (29.8)
1 372 (30.4) 378 (50.8) 750 (38.2)
2 138 (11.3) 26 (3.5) 164 (8.3)
 3 193 (15.8) 61 (8.2) 254 (12.9)
Missing 117 (9.6) 95 (12.8) 212 (10.8)
Diabetes, n (%)
No 1,183 (96.8) 705 (94.8) 1,888 (96.0)
Yes 33 (2.7) 32 (4.3) 65 (3.3)
Missing 6 (0.5) 7 (0.9) 13 (0.7)
Regular physical activity,b n (%)
<3 months 159 (13.0) 86 (11.6) 245 (12.5)
3 months 1,063 (87.0) 658 (88.4) 1,721 (87.5)
Aspirin and/or ibuprofen intake,c n (%)
<1 month 953 (78.0) 614 (82.5) 1,567 (79.7)
1 month 195 (16.0) 90 (12.1) 285 (14.5)
Missing 74 (6.1) 40 (5.4) 114 (5.8)
(Continued)
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Table 1. Continued
Exposure variable No colorectal cancer
(n 5 1222 (62.2%))
Colorectal cancer
(n 5 744 (37.8%))
Total
(n 5 1966)
Cigarette smoking, n (%)
Never smoker 664 (54.3) 337 (45.3) 1,001 (50.9)
Former smokerd 276 (22.6) 156 (21.0) 432 (22.0)
Current smokere 277 (22.7) 250 (33.6) 527 (26.8)
Missing 5 (0.4) 1 (0.1) 6 (0.3)
Average number of alcoholic beverages consumed per dayf
0 309 (25.3) 186 (25.0) 495 (15.2)
 0.5 197 (16.1) 128 (17.2) 325 (16.5)
0.5–1 199 (16.3) 100 (13.4) 299 (15.2)
1–2 169 (13.8) 101 (13.6) 270 (13.7)
2þ 174 (14.2) 136 (18.3) 310 (15.8)
Missing 174 (14.2) 93 (12.5) 267 (13.6)
BMIg at age 20 years, n (%)
Normal 804 (65.8) 470 (63.2) 1,274 (64.8)
Overweight 195 (16.0) 139 (18.7) 334 (17.0)
Obese 48 (3.9) 41 (5.5) 89 (4.5)
Underweight 106 (8.7) 61 (8.2) 167 (8.5)
Missing 69 (5.7) 33 (4.4) 102 (5.2)
BMIg 2 years before diagnosed / censored,h n (%)
Normal 356 (29.1) 92 (12.4) 448 (22.8)
Overweight 236 (19.3) 104 (14.0) 340 (17.3)
Obese 117 (9.6) 58 (7.8) 175 (8.9)
Underweight 24 (2.0) 9 (1.2) 33 (1.7)
Missing 489 (40.0) 481 (64.7) 970 (49.3)
Daily fruit and vegetable intakei 2 years before interview,h n (%)
0–2 197 (16.1) 109 (14.7) 306 (15.6)
2–3 141 (11.5) 44 (5.9) 185 (9.4)
3–4 139 (11.3) 46 (6.2) 184 (9.4)
4þ 274 (22.4) 63 (8.5) 337 (17.1)
Missing 472 (38.6) 482 (64.8) 954 (48.5)
Daily red meat intakei 2 years before interview,h n (%)
0–0.3 220 (18.0) 83 (11.2) 303 (15.4)
0.3–0.6 261 (21.4) 82 (11.0) 343 (17.5)
0.6–0.9 106 (8.7) 43 (5.8) 149 (7.6)
0.9þ 161 (13.2) 55 (7.4) 216 (11.0)
Missing 474 (38.8) 481 (64.7) 955 (48.6)
Number of live births,j n (%)
None 222 (28.9) 60 (17.6) 282 (25.5)
1 80 (10.4) 49 (14.4) 129 (11.6)
2 211 (27.5) 94 (27.6) 305 (27.5)
 3 235 (30.6) 125 (36.7) 360 (32.5)
Missing 19 (2.5) 13 (3.8) 32 (2.9)
Age at menarche,j n (%)
 12 years 204 (26.6) 109 (32.0) 313 (28.3)
13 years 225 (29.3) 90 (26.4) 315 (28.4)
 14 years 319 (41.6) 134 (39.3) 453 (40.9)
Missing 19 (2.5) 8 (2.4) 27 (2.4)
Age at menopause,j n (%)
Pre-menopause 521 (67.9) 228 (66.9) 749 (67.6)
< 50 years 162 (21.1) 88 (25.8) 250 (22.6)
 50 years 50 (6.5) 16 (4.7) 66 (6.0)
Missing 34 (4.4) 9 (2.6) 43 (3.9)
(Continued)
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95% CI 0.38–1.04) but there was no evidence of such an
association in men (P ¼ 0.29) (Table 4).
In the analysis restricted to carriers who were diagnosed
with CRC or censored within 5 years before interview, the
results were similar to the main analysis (Supplementary
Table 3, available as Supplementary data at IJE online). In
the analysis where the outcome was defined as colorectal
neoplasia, the results were similar to the main analysis
(Supplementary Table 4, available as Supplementary data
at IJE online). There was no evidence that main exposure
variables violated the PH assumption in any of the final
models.
Discussion
We found regular intake of multivitamin and/or calcium
supplements for at least 3 yearsto be associated with an ap-
proximate halving of CRC risk for MMR gene mutation
carriers, independently of other factors including aspirin
intake and colonoscopy screening. In our study sample,
multivitamin and calcium supplement intakes were higher
in women and in older people, similar to the pattern
observed by the US National Health and Nutrition
Examination Survey.41
Only one previous study has reported associations be-
tween supplement intake and the risk of colorectal
Table 1. Continued
Exposure variable No colorectal cancer
(n 5 1222 (62.2%))
Colorectal cancer
(n 5 744 (37.8%))
Total
(n 5 1966)
Hormonal contraception,j n (%)
< 1 year 200 (26.1) 94 (27.6) 294 (26.5)
 1 year 558 (72.8) 237 (69.5) 795 (71.8)
Missing 9 (1.2) 10 (2.9) 19 (1.7)
HRT used,j n (%)
< 6 months 641 (83.6) 293 (85.9) 934 (84.3)
 6 months, estrogen only 61 (8.0) 29 (8.5) 90 (8.1)
 6 months, estrogen and progestin 44 (5.7) 12 (3.5) 56 (5.1)
Missing 21 (2.7) 7 (2.1) 28 (2.5)
Multivitamin supplement intake,c, n (%)
Never 830 (67.9) 573 (77.0) 1,403 (71.4)
1 month to 11.9 months 81 (6.6) 25 (3.4) 106 (5.4)
1 year to 2.9 years 82 (6.7) 40 (5.4) 122 (6.2)
 3 years 165 (13.5) 72 (9.7) 237 (12.1)
Missing 64 (5.2) 34 (4.6) 98 (5.0)
Calcium supplement intake,c n (%)
Never 1,045 (85.5) 685 (92.1) 1,730 (88.0)
1 month to 11.9 months 31 (2.5) 4 (0.5) 35 (1.8)
1 year to 2.9 years 41 (3.4) 19 (2.6) 60 (3.1)
 3 years 58 (4.7) 25 (3.4) 83 (4.2)
Missing 47 (3.9) 11 (1.5) 58 (3.0)
Folic acid supplement intake,c n (%)
Never 1,073 (87.8) 693 (93.1) 1,766 (89.8)
1 month to 11.9 months 57 (4.7) 11 (1.5) 68 (3.5)
1 year to 2.9 years 38 (3.1) 18 (2.4) 56 (2.9)
 3 years 22 (1.8) 8 (1.1) 30 (1.5)
Missing 32 (2.6) 14 (1.9) 46 (2.3)
MMR, mismatch repair; BMI, body mass index; HRT, hormone replacement therapy.
aAge at first diagnosis of colorectal cancer or age at first polypectomy or diagnosis of another cancer or age at interview, whichever occurred first.
bRegular physical activity defined as any physical activity for at least 30 min per week for at least 3 months.
cAt least twice a week.
dFormer smokers defined as carriers who had smoked at least 1 cigarette per day for at least 3 months and had quit more than 2 years before age at colorectal
cancer or censored age.
eCurrent smokers defined as carriers who had smoked at least 1 cigarette per day for at least 3 months and continued within 2 years of age at colorectal cancer
or censored age.
f4-oz. glasses of wine, or 12-oz. cans or bottles of beer or hard cider, or 1-oz. servings of sake or liquor (spirits).
gUnderweight (< 18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), obese ( 30 kg/m2).
hCarriers who were diagnosed with colorectal cancer or censored more than 2 years before interview had ‘missing’ for these variables.
iNumber of servings.
jLimited to female carriers.
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Table 2. Prevalence of multivitamin, calcium and folic acid supplement intake at least twice a week for at least 1 month in car-
riers of germline mutation in DNA mismatch repair gene by country, sex and age group
Supplement intake for at least 1 month Country / age group Male n (% of total) Female n (% of total) Overall n (% of total)
Multivitamin USA
 35 17 (20.2) 26 (31.3) 43 (25.8)
36–45 20 (24.1) 41 (41.41) 61 (33.5)
46–55 33 (47.1) 34 (52.3) 67 (49.6)
55þ 19 (43.2) 26 (61.9) 45 (52.3)
All 89 (31.7) 127 (43.9) 216 (37.9)
Australia / New Zealand
 35 39 (23.1) 51 (24.5) 90 (23.9)
36–45 16 (12.9) 35 (19.9) 51 (17.0)
46–55 11 (11.0) 20 (14.7) 31 (13.1)
55þ 6 (10.5) 10 (13.5) 16 (12.2)
All 72 (16.0) 116 (19.5) 188 (18.0)
Canada
 35 6 (21.4) 8 (19.5) 14 (20.3)
36–45 9 (25.7) 12 (22.2) 21 (23.6)
46–55 4 (13.8) 7 (17.5) 11 (15.9)
55þ 5 (41.7) 10 (66.7) 15 (55.6)
All 24 (23.1) 37 (24.7) 61 (24.0)
Overall 185 (22.2) 280 (27.1) 465 (24.9)
Calcium USA
 35 1 (1.1) 9 (10.7) 10 (5.8)
36–45 4 (4.7) 19 (17.3) 23 (11.8)
46–55 8 (11.0) 20 (29.9) 28 (20.0)
55þ 5 (11.1) 23 (50.0) 28 (30.8)
All 18 (6.2) 71 (23.1) 89 (14.9)
Australia / New Zealand
 35 5 (3.0) 11 (5.3) 16 (4.2)
36–45 2 (1.6) 10 (5.7) 12 (4.0)
46–55 2 (2.0) 15 (11.0) 17 (7.2)
55þ 2 (3.5) 18 (25.0) 20 (15.5)
All 11 (2.4) 54 (9.1) 65 (6.2)
Canada
35 1 (3.3) 6 (13.3) 7 (9.3)
36–45 0 (0) 3 (5.8) 3 (3.3)
46–55 1 (3.5) 7 (17.1) 8 (11.4)
55þ 1 (8.3) 5 (33.3) 6 (22.2)
All 3 (2.7) 21 (13.7) 24 (9.1)
Overall 32 (3.8) 146 (13.8) 178 (9.3)
Folic acid USA
 35 0 (0) 9 (10.2) 9 (5.2)
36–45 0 (0) 10 (8.9) 10 (5.1)
46–55 2 (2.7) 6 (8.1) 8 (5.4)
55þ 2 (4.4) 4 (8.9) 6 (6.6)
All 4 (1.4) 29 (9.1) 33 (5.4)
Australia /New Zealand
 35 1 (0.6) 44 (21.3) 45 (12.0)
36–45 1 (0.8) 34 (19.3) 35 (11.6)
46–55 1 (1.0) 12 (8.8) 13 (5.5)
55þ 3 (5.3) 6 (8.1) 9 (6.9)
All 6 (1.3) 96 (16.2) 102 (9.8)
Canada
 35 0 (0) 5 (11.9) 5 (6.9)
(Continued)
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adenoma in Lynch syndrome.42 The prospective study of
470 MMR gene mutation carriers reported no evidence of
an association between colorectal adenoma risk and multi-
vitamin intake (HR 1.15, 95% CI 0.72–1.84) or calcium
supplement intake (HR 0.69, 95% CI 0.25–1.92).
Although the results of this study are not overall contrary
to our results (overlapping CIs, especially for calcium sup-
plement intake), different definitions of supplement intake
used in the studies (during the past month vs at least twice
a week for at least 1 month), study sample (470 carriers
and 122 colorectal adenoma cases vs 1966 carriers and
744 CRC cases) and outcome definition (colorectal aden-
oma vs CRC) may explain the stronger inverse association
observed in our study.
Similar to our finding of an inverse association between
multivitamin supplement intake and CRC risk for MMR
gene mutation carriers, a prospective study previously re-
ported that multivitamin supplement intake was associated
with a lowering of the excess risk of colon cancer for a per-
son having a first-degree relative affected by CRC (a cohort
more likely to carry CRC-predisposing gene mutations
than the general population).43 For the general population,
multivitamin supplement intake has also been shown to
have an inverse association with CRC risk. A large
randomized controlled trial showed a small protective ef-
fect of multivitamin supplements on the risk of cancers,
including colorectal cancer for men.44 A pooled analysis of
prospective cohort studies reported that ever use of multi-
vitamin supplements was associated with a 12% lower risk
of colon cancer compared with never use [relative risk
(RR) 0.88, 95% CI 0.81–0.96].26
We also found an inverse association between calcium
supplement intake and CRC risk for MMR gene mutation
carriers. Two case-control studies have investigated the as-
sociation between dietary calcium intake and CRC with and
without MSI, a feature that indicates loss of MMR function
due to either somatic methylation or inherited MMR gene
mutations.45,46 Similar to our results, both of these studies
reported inverse associations between dietary calcium intake
and MSI-high CRC. A meta-analysis of randomized con-
trolled trials47 showed a protective effect of calcium supple-
mentation against recurrent colorectal adenoma (RR 0.80,
95% CI 0.68–0.93) although a recent trial48 showed no
such association. A meta-analysis of 24 prospective cohort
studies also reported an inverse association between calcium
supplement intake and CRC risk for the general population
(RR 0.86, 95% CI 0.79–0.95).27
Given that our estimates for the strengths of associ-
ations between multivitamin and calcium supplement in-
takes and CRC risk for MMR gene mutation carriers were
stronger than those for the general population (P < 0.05),
it could be suggested that, if the association is causal, the
possibly protective effect of multivitamin and calcium on
CRC is likely to be stronger for those with MMR gene mu-
tations. However, we were only able to report the overall
effect of multivitamins rather than individual vitamins and
minerals in the current study. Further, data on dosage and
composition of multivitamins were not available in our
database. The underlying mechanism of a potential benefi-
cial role of multivitamins in the prevention of CRC is not
clear, but it has been hypothesized to be due to potential
chemopreventive roles of several single vitamins and min-
erals included in the multivitamin supplement.
The relationship between folic acid supplements or diet-
ary folate intake and CRC is complex. A large-scale meta-
analysis showed that intake of folic acid supplements or
dietary folate had a small inverse association with CRC for
the general population, although the findings were incon-
sistent depending on dose, duration and source in studies
that were conducted mainly before widespread fortification
of the food supply with folic acid.28 The role of supplemen-
tal folic acid, the non-natural folate form currently used in
all supplements, on cancer risk in the post-fortification
period is controversial.49–56 Two prospective cohort studies
reported no evidence for an association between total folate
intake, from both diet and supplements, and the risk of
MSI-high CRCs (although the MSI-high CRCs in these stud-
ies were predominantly sporadic).57,58 Similarly, in the cur-
rent study, where the majority of carriers were queried
about folic acid supplement intake after 1996 when wide-
spread voluntary fortification began in the USA, Canada
and Australia, no evidence of an association between folic
acid supplement intake and CRC risk for a high-risk post-
fortification population was observed. However, the lack of
Table 2. Continued
Supplement intake for at least 1 month Country / age group Male n (% of total) Female n (% of total) Overall n (% of total)
36–45 0 (0) 7 (13.0) 7 (7.5)
46–55 0 (0) 4 (8.9) 4 (5.7)
55þ 1 (8.3) 2 (11.1) 3 (10.0)
All 1 (0.9) 18 (11.3) 19 (7.1)
Overall 11 (1.3) 143 (13.3) 154 (8.0)
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an observed association between folate intake and CRC risk
in this study might be attributed to poor statistical power.
Our study is, to the best of our knowledge, the largest
study to date investigating associations between multivita-
min, calcium and folic acid supplement intake and CRC
risk for MMR gene mutation carriers. To overcome bias in
retrospective studies when subjects are selected on the basis
of phenotype, we used a weighted cohort approach.33 The
data for this study came from the Colon Cancer Family
Registry where we have used standardized and uniform
materials for collection of epidemiological and cancer data
as well as genetic testing.29
The current study findings may have been affected by
recall or response bias, given that data of the intake of
multivitamin, calcium and folic acid supplements (and the
other variables) were collected at the time of recruitment
after the diagnoses of CRC had occurred. There may be re-
sidual confounding in the current study due to lack of
high-quality data of dietary intake, total energy intake,
physical activity and recent BMI. As carriers with poor sur-
vival were less likely to be included in the analysis, because
they were unable to provide a blood sample for genetic
testing and complete a questionnaire, there is a possibility
of survival and selection bias if age at onset and survival of
cases were related to exposure variables and/or mutation
status. To determine whether survival bias influenced the
observed associations, we conducted a sensitivity analysis
restricted to carriers who were diagnosed with CRC or
censored within 5 years before interview; we observed
findings similar to the main analysis. Further, we were not
able to investigate the association with vitamin D in com-
bination with calcium intake. We were also not able to re-
port the dose-response relationships with CRC risk, as
information on the specific doses of supplements intake
was not available. Our definition of duration of supple-
ments intake was based on the assumption that the intake
was continuous and recent before the interview. However,
participants might have used supplements intermittently,
and we were unable to account for this variation in our
analysis. In addition, immortal time bias is a potential limi-
tation of our analysis because we did not have data on the
carriers’ age at first intake of supplements and were not
able to use a time-dependent approach. Our analytical
approach might have overestimated the association
between intake of supplements and the risk of CRC.
Another limitation is that we were only able to report the
overall effect of multivitamins rather than individual vita-
mins and minerals.
In conclusion, we found intake of multivitamin and cal-
cium supplements to be associated with a decreased risk of
CRC for MMR gene mutation carriers. Further prospective
studies and clinical trials are required to confirm this
finding, as it might provide evidence on important options
to reduce CRC risk for these high-risk people.
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